{"id":"measles-mumps-rubella-varicella-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (erythema, swelling, pain)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Parotitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The MMRV vaccine is a live attenuated vaccine combining four separate viral vaccines into a single formulation. Each component virus is weakened so it cannot cause disease but retains sufficient immunogenicity to trigger both humoral (antibody) and cell-mediated immune responses. This dual immune activation provides long-term protection against infection with wild-type measles, mumps, rubella, and varicella-zoster viruses.","oneSentence":"This vaccine stimulates the immune system to produce antibodies and cellular immunity against measles, mumps, rubella, and varicella viruses by introducing attenuated (weakened) forms of all four viruses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:26.293Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of measles, mumps, rubella, and varicella in children and adolescents"}]},"trialDetails":[{"nctId":"NCT05923970","phase":"","title":"Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2024-11-09","conditions":"Vaccination Failure, Vaccine Response Impaired","enrollment":200},{"nctId":"NCT06824194","phase":"PHASE3","title":"Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-02-18","conditions":"Pneumococcal Immunization","enrollment":2320},{"nctId":"NCT07348692","phase":"PHASE3","title":"Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-01-20","conditions":"Pneumococcal Immunization, Healthy Volunteers","enrollment":896},{"nctId":"NCT06824181","phase":"PHASE3","title":"Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-02-27","conditions":"Pneumococcal Immunization","enrollment":580},{"nctId":"NCT07406360","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-04-13","conditions":"Measles","enrollment":1209},{"nctId":"NCT03621670","phase":"PHASE3","title":"Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-07-27","conditions":"Infections, Meningococcal","enrollment":1196},{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT06806137","phase":"PHASE3","title":"A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-05-15","conditions":"Chickenpox","enrollment":600},{"nctId":"NCT06855160","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-04-17","conditions":"Chickenpox","enrollment":900},{"nctId":"NCT06038617","phase":"PHASE4","title":"Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children","status":"COMPLETED","sponsor":"Duke University","startDate":"2023-10-30","conditions":"Fever After Vaccination, Fever, Seizures Fever","enrollment":344},{"nctId":"NCT04398706","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-05-22","conditions":"Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":852},{"nctId":"NCT05630846","phase":"PHASE2","title":"A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-12-14","conditions":"Measles; Mumps; Rubella; Chickenpox, Measles","enrollment":801},{"nctId":"NCT00505063","phase":"PHASE2","title":"Prospective Trial of Vaccine Responses in Childhood Cancer Survivors","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-07-10","conditions":"Childhood Cancer, Multiple Diseases","enrollment":76},{"nctId":"NCT06740630","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-01-10","conditions":"Chickenpox","enrollment":1840},{"nctId":"NCT05084508","phase":"PHASE2","title":"A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-02-03","conditions":"Chickenpox","enrollment":800},{"nctId":"NCT06693895","phase":"PHASE3","title":"A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-11-26","conditions":"Chickenpox","enrollment":750},{"nctId":"NCT03537508","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-25","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2627},{"nctId":"NCT03691610","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-04","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":950},{"nctId":"NCT06333275","phase":"","title":"Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-11-14","conditions":"Vaccine Immunity in CAR-T Cell Therapy Recipients","enrollment":80},{"nctId":"NCT03673462","phase":"PHASE3","title":"Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2797},{"nctId":"NCT05952505","phase":"PHASE4","title":"Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated Vaccines","status":"UNKNOWN","sponsor":"Shanghai Municipal Center for Disease Control and Prevention","startDate":"2023-08","conditions":"SARS-CoV-2 Infection, Varicella, Measles","enrollment":540},{"nctId":"NCT04016714","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-08-28","conditions":"Pneumococcal Infections","enrollment":1191},{"nctId":"NCT03180359","phase":"NA","title":"Vaccines Immunogenicity in Renal, Hepatic, Cardiac or Pulmonary Transplanted Children","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2016-01-01","conditions":"Transplantation","enrollment":55},{"nctId":"NCT03620162","phase":"PHASE3","title":"A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-18","conditions":"Pneumococcal Infections","enrollment":900},{"nctId":"NCT03205371","phase":"PHASE3","title":"Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-11-07","conditions":"Meningitis, Meningococcal","enrollment":1183},{"nctId":"NCT01049035","phase":"PHASE2","title":"A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12-16","conditions":"Meningitis, Meningococcal Infection","enrollment":580},{"nctId":"NCT05095844","phase":"","title":"National Vaccine Adverse Event Reporting Survey and Etiology","status":"UNKNOWN","sponsor":"Neuroganics LLC","startDate":"2022-03-15","conditions":"COVID-19, Vaccine Adverse Reaction, Vaccine Reaction","enrollment":100000},{"nctId":"NCT00432523","phase":"PHASE3","title":"Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-01-20","conditions":"Measles, Mumps, Varicella","enrollment":752},{"nctId":"NCT03239873","phase":"PHASE3","title":"Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-17","conditions":"Varicella","enrollment":600},{"nctId":"NCT01681992","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10-10","conditions":"Measles, Mumps, Rubella","enrollment":4538},{"nctId":"NCT02184572","phase":"PHASE3","title":"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-08-25","conditions":"Measles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine","enrollment":1742},{"nctId":"NCT00861744","phase":"PHASE2","title":"Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-03","conditions":"Rubella, Mumps, Measles","enrollment":1259},{"nctId":"NCT01621802","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-06-21","conditions":"Measles-Mumps-Rubella","enrollment":4011},{"nctId":"NCT01702428","phase":"PHASE3","title":"Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-11-09","conditions":"Rubella, Measles, Mumps","enrollment":5016},{"nctId":"NCT00474266","phase":"PHASE3","title":"Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06-05","conditions":"Infections, Meningococcal","enrollment":1000},{"nctId":"NCT00092430","phase":"PHASE3","title":"Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-09-26","conditions":"Measles, Mumps, Rubella","enrollment":1200},{"nctId":"NCT00892775","phase":"PHASE2","title":"Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-03","conditions":"Measles, Varicella, Mumps","enrollment":501},{"nctId":"NCT00226499","phase":"PHASE3","title":"Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-09-01","conditions":"Varicella, Chickenpox Vaccines","enrollment":5803},{"nctId":"NCT02712177","phase":"","title":"Bexsero™and Routine Infant Vaccines: Effect of Coadministration on the Safety of Immunization","status":"COMPLETED","sponsor":"CHU de Quebec-Universite Laval","startDate":"2008-08","conditions":"Meningococcal Infections","enrollment":4535},{"nctId":"NCT01341639","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-05-26","conditions":"Bacterial Infections, Virus Diseases","enrollment":1250},{"nctId":"NCT02687763","phase":"EARLY_PHASE1","title":"Safety and Efficacy of ProQuad® in Children 6-24 Month Being Evaluated for Solid Organ Transplant","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2015-12","conditions":"RENAL INSUFFICIENCY, CHRONIC, LIVER FAILURE, ACUTE, HEART DISEASE","enrollment":5},{"nctId":"NCT00326183","phase":"PHASE4","title":"Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-03-26","conditions":"Hepatitis A, Measles, Mumps","enrollment":1800},{"nctId":"NCT01536405","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-06-05","conditions":"Measles, Mumps, Rubella","enrollment":1412},{"nctId":"NCT02062502","phase":"PHASE3","title":"Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-03-07","conditions":"Varicella","enrollment":611},{"nctId":"NCT00578175","phase":"PHASE2","title":"Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-11-20","conditions":"Varicella, Rubella, Mumps","enrollment":1851},{"nctId":"NCT00310856","phase":"PHASE2","title":"Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2005-06","conditions":"Meningococcal Meningitis","enrollment":175},{"nctId":"NCT00289783","phase":"PHASE3","title":"Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-02-22","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":4441},{"nctId":"NCT00871117","phase":"PHASE3","title":"Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03-31","conditions":"Tetanus, Acellular Pertussis, Diphtheria","enrollment":478},{"nctId":"NCT01506193","phase":"PHASE3","title":"Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-02-06","conditions":"Rubella, Varicella, Measles","enrollment":716},{"nctId":"NCT00402831","phase":"PHASE3","title":"ProQuad® Intramuscular vs Subcutaneous","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-10-06","conditions":"Measles, Mumps, Rubella","enrollment":405},{"nctId":"NCT00197015","phase":"PHASE3","title":"Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-10-06","conditions":"Hepatitis A","enrollment":1474},{"nctId":"NCT00969436","phase":"PHASE3","title":"Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11-09","conditions":"Varicella, Rubella, Mumps","enrollment":450},{"nctId":"NCT00751348","phase":"PHASE3","title":"Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-10-01","conditions":"Measles, Varicella, Mumps","enrollment":475},{"nctId":"NCT00432042","phase":"PHASE3","title":"Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-01-12","conditions":"Varicella, Measles, Mumps","enrollment":955},{"nctId":"NCT00566527","phase":"PHASE3","title":"Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-11-29","conditions":"Measles, Mumps, Rubella","enrollment":1620},{"nctId":"NCT00560755","phase":"PHASE3","title":"Safety Study of ProQuad® rHA in Infants (V221-037)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-10-24","conditions":"Measles, Mumps, Rubella","enrollment":3388},{"nctId":"NCT03107312","phase":"","title":"Bioarray for the Serological Assessment of Immunity Against Vaccine-preventable Infections","status":"UNKNOWN","sponsor":"Jena University Hospital","startDate":"2017-04-01","conditions":"Immunization; Infection","enrollment":900},{"nctId":"NCT00312858","phase":"PHASE4","title":"Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-04","conditions":"Hepatitis A Virus","enrollment":653},{"nctId":"NCT00822237","phase":"PHASE3","title":"Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process) (Study V210-057) (Completed)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-01","conditions":"Varicella","enrollment":598},{"nctId":"NCT00839917","phase":"PHASE3","title":"A Study of ProQuad™ in Healthy Children in Korea (V221-023)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-02","conditions":"Measles, Mumps, Rubella","enrollment":30},{"nctId":"NCT00109343","phase":"PHASE3","title":"V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-03","conditions":"Measles, Mumps, Rubella","enrollment":1027},{"nctId":"NCT00432731","phase":"PHASE4","title":"Safety Study of a Refrigerator-stable Formulation of VARIVAX®","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-12","conditions":"Varicella, Measles, Mumps","enrollment":500},{"nctId":"NCT00345683","phase":"PHASE3","title":"Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":4021},{"nctId":"NCT00370227","phase":"PHASE3","title":"Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10","conditions":"Infections, Streptococcal","enrollment":390},{"nctId":"NCT00352898","phase":"PHASE2","title":"Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-04","conditions":"Mumps, Rubella, Measles","enrollment":400},{"nctId":"NCT00353288","phase":"PHASE2","title":"Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-03","conditions":"Varicella, Rubella, Measles","enrollment":446},{"nctId":"NCT00127010","phase":"PHASE3","title":"Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-11","conditions":"Measles, Rubella, Mumps","enrollment":""},{"nctId":"NCT00127023","phase":"PHASE3","title":"Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-05","conditions":"Mumps, Varicella, Rubella","enrollment":944},{"nctId":"NCT00126997","phase":"PHASE4","title":"Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-05","conditions":"Mumps, Rubella, Measles","enrollment":1439},{"nctId":"NCT00406211","phase":"PHASE3","title":"Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-07","conditions":"Rubella, Varicella, Mumps","enrollment":398},{"nctId":"NCT00483574","phase":"PHASE3","title":"Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-05","conditions":"Meningococcal Meningitis, Measles, Mumps","enrollment":1378},{"nctId":"NCT00384397","phase":"PHASE3","title":"A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-09","conditions":"Meningococcal Meningitis, Measles, Mumps","enrollment":1128},{"nctId":"NCT00422292","phase":"PHASE3","title":"Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-12","conditions":"Meningococcal Meningitis, Measles, Mumps","enrollment":1664},{"nctId":"NCT02712203","phase":"","title":"MMR and MMRV Vaccines: Effect of Age at First Dose on Safety and Immunogenicity of the Measles Component.","status":"UNKNOWN","sponsor":"CHU de Quebec-Universite Laval","startDate":"2004-07","conditions":"Measles","enrollment":5808},{"nctId":"NCT00985153","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2000-03","conditions":"Measles, Mumps, Rubella","enrollment":3927},{"nctId":"NCT00092391","phase":"PHASE3","title":"A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1999-02","conditions":"Measles, Mumps, Rubella","enrollment":1997},{"nctId":"NCT00975507","phase":"PHASE3","title":"ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1998-03","conditions":"Measles, Mumps, Rubella","enrollment":480},{"nctId":"NCT00984295","phase":"PHASE3","title":"Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2000-06","conditions":"Measles, Mumps, Rubella","enrollment":1913},{"nctId":"NCT00985166","phase":"PHASE3","title":"A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2000-08","conditions":"Measles, Mumps, Rubella","enrollment":801},{"nctId":"NCT01346293","phase":"PHASE3","title":"Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-04","conditions":"Tetanus, Diphtheria, Pertussis","enrollment":3372},{"nctId":"NCT00986232","phase":"PHASE2","title":"ProQuad Dose Selection Study (V221-011)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1999-04","conditions":"Measles, Mumps, Rubella","enrollment":1551},{"nctId":"NCT00847145","phase":"PHASE3","title":"Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-02","conditions":"Meningococcal Disease","enrollment":2249},{"nctId":"NCT00474526","phase":"PHASE3","title":"A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-03","conditions":"Meningitis, Meningococcal","enrollment":4545},{"nctId":"NCT01544764","phase":"NA","title":"Examining Adolescent Assessment, Feedback, Incentive, and Exchange (AFIX) in North Carolina","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2011-04","conditions":"Adolescent Health Services, Immunization","enrollment":91},{"nctId":"NCT01738841","phase":"","title":"Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the Philippines","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2013-08","conditions":"Mumps, Rubella, Measles","enrollment":""},{"nctId":"NCT00806195","phase":"PHASE3","title":"Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-12","conditions":"Meningitis, Meningococcal Infection","enrollment":7744},{"nctId":"NCT00626327","phase":"PHASE3","title":"Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-02","conditions":"Meningococcal Infections","enrollment":1630},{"nctId":"NCT00373958","phase":"PHASE3","title":"Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-09","conditions":"Vaccines, Pneumococcal","enrollment":666},{"nctId":"NCT01064141","phase":"PHASE2","title":"A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-01","conditions":"Dengue Fever, Dengue Hemorrhagic Fever","enrollment":210},{"nctId":"NCT00138255","phase":"","title":"Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella Vaccines","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-06","conditions":"Measles, Mumps, Rubella","enrollment":32},{"nctId":"NCT00258726","phase":"PHASE1, PHASE2","title":"Immune Responses to Two Dose Varivax +/- MMR-II","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-10","conditions":"Measles, Mumps, Rubella","enrollment":105},{"nctId":"NCT00351923","phase":"PHASE3","title":"Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-03","conditions":"Measles, Mumps, Rubella","enrollment":330},{"nctId":"NCT00192491","phase":"PHASE3","title":"Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2000-12","conditions":"Influenza","enrollment":1200},{"nctId":"NCT00329251","phase":"PHASE4","title":"Study of the Influence of Vaccination in HIV Viral Load and Immunologic Responses Against HIV","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2003-04","conditions":"HIV","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":65,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MMRV: ProQuad"],"phase":"phase_3","status":"active","brandName":"Measles-mumps-rubella-varicella vaccine","genericName":"Measles-mumps-rubella-varicella vaccine","companyName":"Sanofi Pasteur, a Sanofi Company","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to produce antibodies and cellular immunity against measles, mumps, rubella, and varicella viruses by introducing attenuated (weakened) forms of all four viruses. Used for Prevention of measles, mumps, rubella, and varicella in children and adolescents.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}